GlassScriptPhysician profile
Marlee Chang
NPI 1104353937
$1,397.19
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $942 · 2022: $455.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $320.54 | 2021-2022 | |
| Neurelis, INC. | $279.01 | 2021-2022 | |
| Eisai INC. | $226.57 | 2021-2022 | |
| Tris Pharma INC | $119.58 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $110.29 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $79.08 | 2022 | |
| Supernus Pharmaceuticals, INC. | $63.28 | 2021-2022 | |
| Corium, LLC | $58.61 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $45.14 | 2021 | |
| Allergan, INC. | $26.15 | 2022 | |
| Biogen, INC. | $20.63 | 2021 | |
| Aquestive Therapeutics, INC. | $20.26 | 2022 | |
| Ns Pharma, INC. | $15.53 | 2021 | |
| Ironshore Pharmaceuticals INC. | $12.52 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlee Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.